- Home
- CGEN vs PRME Comparison
CGEN vs PRME Comparison
Compare CGEN & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- PRME
- Stock Information
- Founded
- CGEN 1993
- PRME 2019
- Country
- CGEN Israel
- PRME United States
- Employees
- CGEN N/A
- PRME N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- PRME Medicinal Chemicals and Botanical Products
- Sector
- CGEN Health Care
- PRME Health Care
- Exchange
- CGEN Nasdaq
- PRME Nasdaq
- Market Cap
- CGEN 167.4M
- PRME 191.7M
- IPO Year
- CGEN 2000
- PRME 2022
- Fundamental
- Price
- CGEN $1.43
- PRME $3.57
- Analyst Decision
- CGEN
- PRME Buy
- Analyst Count
- CGEN 0
- PRME 6
- Target Price
- CGEN N/A
- PRME $8.88
- AVG Volume (30 Days)
- CGEN 217.0K
- PRME 4.4M
- Earning Date
- CGEN 08-06-2025
- PRME 08-07-2025
- Dividend Yield
- CGEN N/A
- PRME N/A
- EPS Growth
- CGEN N/A
- PRME N/A
- EPS
- CGEN N/A
- PRME N/A
- Revenue
- CGEN $22,144,000.00
- PRME $4,961,000.00
- Revenue This Year
- CGEN N/A
- PRME $126.92
- Revenue Next Year
- CGEN $105.77
- PRME $87.32
- P/E Ratio
- CGEN N/A
- PRME N/A
- Revenue Growth
- CGEN N/A
- PRME 739.42
- 52 Week Low
- CGEN $1.13
- PRME $1.11
- 52 Week High
- CGEN $2.66
- PRME $5.17
- Technical
- Relative Strength Index (RSI)
- CGEN 37.47
- PRME 46.93
- Support Level
- CGEN $1.43
- PRME $3.35
- Resistance Level
- CGEN $1.53
- PRME $3.88
- Average True Range (ATR)
- CGEN 0.06
- PRME 0.38
- MACD
- CGEN 0.00
- PRME -0.12
- Stochastic Oscillator
- CGEN 44.44
- PRME 16.00
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.